報價延遲最少15分鐘:2024/11/10 16:59 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
66.23 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
2.43/2.66
|
|
企業價值
40.33B
|
| 資產負債 |
|
每股賬面淨值
12.35
|
| 現金流量 |
|
現金流量率
0.02
|
| 損益表 |
|
收益
6.00B
|
|
每股收益
9.66
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/11/10 16:59 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US. |